Hester Biosciences Net Profit up by 41% in Q3 of FY 2015-16

hester25 January 2016

 

Financial Highlights

INR in Crores

  Q3 9 Months
FY 16 FY 15 Growth FY 16 FY 15 Growth
Net Sales 24.17 21.88 10% 72.71 66.68 9%
Net Profit 4.76 3.37 41% 13.72 10.46 31%
EPS in INR 5.59 3.96 41% 16.13 12.29 31%

Q3 Highlights

  1. Hester has reported a Net Sales of INR 24.17 Cr in Q3FY16 as compared to INR 21.88 Cr for the previous corresponding period, thereby registering a growth of 10%.
  2. Net Profit for Q3FY16 is recorded at INR 4.76 Cr as against INR 3.37 Cr for the previous corresponding period, thereby registering a growth of 41%.
  3. Earnings Per Share for the Q3FY16 is at INR 5.59 as against INR 3.96 for Q3FY15.

9 Months Highlights

  1. Hester has reported a Net Sales of INR 72.71 Cr in Nine months FY16 as compared to INR 66.68 Cr for the previous corresponding period, thereby registering a growth of 9%.
  2. Net Profit for Nine months ended FY16 is recorded at INR 13.72 Cr as against INR 10.46 Cr for the previous corresponding period, thereby registering a growth of 31%.
  3. Earnings Per Share for Nine months ended FY16 is at INR 16.13 as against INR 12.29 for the Nine months ended FY15.

Business Overview

 

Sales

  • With poultry vaccines still being the primary contributor towards sales, the recent slump in the poultry industry impacted the sales of poultry vaccines and health products. Poultry meat and egg producers were unable to recover their production costs thereby resulting into decrease in the poultry population across the country. The situation has considerably improved since mid December 2015 and the industry is back on an upswing.
  • Large animal vaccines and health products together have grown by 33% cumulatively in 9 months as compared to last year.
  • Exports are growing faster than the forecasts.
  • Our current imperative remains to increase the sales contribution of the large animal divisions thereby having a balanced topline.

Nepal plant

The challenging social, political and economic environment continues to daunt us. Trial production has commenced at the Nepal plant.

1
➤